Loading...
Docoh

Aprea Therapeutics (APRE)

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company's lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for MDS, Fast Track designation from the FDA for AML, and Orphan Drug designation from the European Commission for MDS, AML and ovarian cancer. APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration.

Company profile

APRE stock data

Analyst ratings and price targets

Last 3 months

Calendar

12 Aug 22
25 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 39.06M 39.06M 39.06M 39.06M 39.06M 39.06M
Cash burn (monthly) 2.86M 2.56M 32.82M 10.32M 2.97M 2.73M
Cash used (since last report) 8.15M 7.29M 93.42M 29.36M 8.45M 7.78M
Cash remaining 30.91M 31.77M -54.36M 9.7M 30.62M 31.28M
Runway (months of cash) 10.8 12.4 -1.7 0.9 10.3 11.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
28 Jul 22 Coiante Scott M Common Stock Grant Acquire A No No 0 60,800 0 145,065
28 Jul 22 Coiante Scott M Stock Option Common Stock Grant Acquire A No No 1.09 89,200 97.23K 89,200
28 Jul 22 Marc Duey Common Stock Grant Acquire A No No 0 5,995 0 157,899
28 Jul 22 Marc Duey Stock Option Common Stock Grant Acquire A No No 1.09 29,575 32.24K 29,575
28 Jul 22 Grissinger Michael Common Stock Grant Acquire A No No 0 5,995 0 5,995
28 Jul 22 Grissinger Michael Stock Option Common Stock Grant Acquire A No No 1.09 29,575 32.24K 29,575
28 Jul 22 Oren Gilad Common Stock Grant Acquire A No No 0 101,300 0 330,314
28 Jul 22 Oren Gilad Stock Option Common Stock Grant Acquire A No No 1.09 148,700 162.08K 148,700
28 Jul 22 Korbel Gregory Alan Common Stock Grant Acquire A No No 0 24,300 0 45,762
28 Jul 22 Korbel Gregory Alan Stock Option Common Stock Grant Acquire A No No 1.09 35,700 38.91K 35,700
29.0% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 37 44 -15.9%
Opened positions 3 8 -62.5%
Closed positions 10 10
Increased positions 11 8 +37.5%
Reduced positions 11 17 -35.3%
13F shares Current Prev Q Change
Total value 14.82M 31.02M -52.2%
Total shares 6.79M 7.18M -5.6%
Total puts 12K 10.2K +17.6%
Total calls 506.5K 522K -3.0%
Total put/call ratio 0.0 0.0 +21.2%
Largest owners Shares Value Change
HealthCap VII 2.37M $0 0.0%
KDev Investments AB 1.78M $8.76M 0.0%
5AM Ventures IV 619.16K $4.55M 0.0%
Vanguard 355.49K $266K 0.0%
MS Morgan Stanley 351.84K $264K +42.5%
Renaissance Technologies 311.75K $234K +4.7%
BLK Blackrock 186.78K $140K -18.8%
Geode Capital Management 150.14K $111K 0.0%
Jane Street 71.96K $54K NEW
Susquehanna International 61.96K $46K -44.4%
Largest transactions Shares Bought/sold Change
Kennedy Capital Management 0 -334.8K EXIT
MS Morgan Stanley 351.84K +104.89K +42.5%
Jane Street 71.96K +71.96K NEW
Citadel Advisors 18.88K -58.2K -75.5%
Susquehanna International 61.96K -49.41K -44.4%
Susquehanna Fundamental Investments 0 -49.1K EXIT
BLK Blackrock 186.78K -43.39K -18.8%
Two Sigma Investments 60.38K +41.77K +224.5%
D. E. Shaw & Co. 49.75K +32.87K +194.7%
JPM JPMorgan Chase & Co. 4 -29.51K -100.0%

Financial report summary

?
Management Discussion
  • Research and development expenses for the three months ended June 30, 2022 were $6.8 million, compared to $6.7 million for the three months ended June 30, 2021. The overall increase of $0.1 million was primarily due to the overall activity in connection with the wrap up and close out of the clinical trials of eprenetapopt as follows:
  • General and administrative expenses for the three months ended June 30, 2022 were $15.6 million, compared to $3.3 million for the three months ended June 30, 2021. The increase of $12.3 million was primarily related to
  • Acquired IPR&D expense was $76.0 million for the three months ended June 30, 2022. Acquired IPR&D resulted from the Atrin Acquisition in May 2022 which was accounted for as an asset acquisition. The acquisition cost allocated to acquired IPR&D with no alternative future use was recorded as an expense as of the closing date of the Atrin Acquisition. No acquired IPR&D expense was incurred in the three months ended June 30, 2021.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: abandon, abandonment, abbreviated, abroad, abrogated, Absence, absent, abuse, abusive, academic, accelerate, accelerated, accessed, accessing, adapt, Addendum, addressing, adequacy, adherence, adjacent, administered, administering, advantage, advertising, advice, advisory, affinity, afford, afforded, AG, agency, agent, allegation, allege, alleged, alleging, alongside, alternative, alternatively, altogether, America, ANDA, anticancer, API, appointing, appointment, approach, April, arbitrage, arbitration, area, arrest, art, assign, assigned, assigning, assignment, assumed, assuming, AstraZeneca, ATRIZE, attack, attain, attempt, attempted, attestation, Attorney, auditor, aware, bar, Bayer, begin, beginning, begun, beneficial, beneficially, bill, bioequivalent, biological, biometric, blinding, blocking, body, box, boxed, branch, breach, breached, Brexit, bring, broad, broader, broadly, brought, budgetary, built, calendar, California, Canada, capability, capable, cast, CCPA, CFC, cGMP, Chairman, Chancery, Chapter, charged, charter, Checkpoint, chemical, chemistry, chemotherapy, Christian, Circuit, circumvent, civil, CJEU, clarifying, clear, closure, Coiante, collapse, Colorado, committee, commonplace, compelled, compete, competing, competitor, compliant, complicate, compromise, compromised, compulsory, conception, conclusive, confidence, confidential, confidentiality, conflicting, Connecticut, consent, constipation, constrain, contamination, contemplate, contend, context, contractor, contraindication, conventional, Conviction, cooperation, core, correction, correspondingly, Corrupt, corruption, Cosmetic, Council, counter, court, coverage, CPA, CPRA, create, created, creating, creation, credible, criminal, crystalline, cured, cyber, cybersecurity, cycle, cyclin, cyclization, database, death, debarment, debilitating, decision, dedicate, defective, defense, defensive, deletion, delivered, delivery, demand, denial, deny, Department, departure, depressing, depriving, description, desirable, desire, desired, detain, detect, detected, deter, deteriorating, devaluation, devalued, device, devise, diagnosing, die, difficult, difficulty, diligence, diminish, diminished, disadvantage, disagree, disclaimed, discounting, discourage, discretion, disgorgement, displace, disposal, disproportionate, dispute, disqualification, disrupt, disrupted, disruption, dissemination, distinct, distract, distracting, distraction, district, divergent, diversion, divert, division, doctrine, document, documentary, documentation, documented, DOJ, domain, domestic, double, downgrade, Doylestown, Dr, draft, drop, dropout, dropping, duly, durable, duty, ease, editing, educating, education, EEA, efficient, efficiently, EMA, employ, employed, enacted, enactment, encompassing, endeavor, endonuclease, enrich, entail, entry, environmental, enzyme, epidemic, EPO, eprenetatopt, erase, erosion, error, essential, essentially, etiology, EU, Europe, evidentiary, exceeding, exclusion, exclusive, exclusivity, exert, expertise, export, extreme, facilitate, fact, factor, factual, fairly, fall, false, faster, fatigue, FCPA, FDCA, feasibility, feasible, febrile, fee, fewer, fiduciary, field, firm, flammable, forego, foregoing, forum, found, fraud, frequently, frustrate, fully, fundamental, furnish, gathered, GCP, GDPR, genetic, genomic, geographic, Gilad, GILTI, global, globally, goal, golden, good, goodwill, governmental, grace, greater, Gregory, ground, grow, Guide, guiding, halt, handling, Harmonization, healthy, hinder, HIPAA, history, HITECH, Holdco, hospital, hostile, human, ICH, ideal, illegally, impede, import, important, Importantly, importation, importing, imposition, impossible, imprisonment, improper, improve, improved, improvement, improving, inability, inadequate, inadvertent, inadvertently, inapplicable, inappropriate, inappropriately, incentive, inconclusive, inconsistent, inconvenient, increasingly, indefinitely, Indictment, induce, ineffective, inflation, influence, influenced, influencing, ingredient, inhibit, inhibited, inhibition, inhibitor, inhibitory, injunction, injured, injury, innovative, inside, inspection, inspectional, instability, instance, institute, instituted, institution, institutional, insufficient, insufficiently, intangible, intensify, intent, intention, intentional, intentionally, inter, interaction, interference, internationally, interplay, interpretation, interpreted, interrupt, interruption, introduction, invalid, invalidate, invalidated, invalidity, invent, invention, inventor, inventorship, invite, IRB, Ireland, irreparable, issuable, jeopardize, jeopardizing, joint, jointly, judicial, Jumpstart, Justice, justify, kinase, Kingdom, knowingly, knowledge, Korbel, labeling, lack, lag, launch, laundering, lawfully, learn, learned, learning, left, legislation, legislative, legislature, lengthy, Leveraging, liable, life, likelihood, Likewise, literature, logistical, lost, lower, Lynparza, MAA, machine, macrocyclic, malfeasance, managerial, mandatory, manipulated, manner, marketplace, meaningful, mechanism, media, Medicaid, Medicare, medicinal, member, merged, merging, merit, methodology, minimizing, minimum, misconduct, mislabeling, misleading, misused, mitigate, Mitigation, moderately, modification, moiety, molecular, monetary, moved, narrowed, narrower, narrowing, narrowly, nasdaq, nausea, NCE, neutropenia, newly, nonbinding, nonclinical, nonrenewal, Northern, Notably, notice, novelty, occurrence, official, oncogene, oncogenic, operationally, opportunity, opposition, opt, ordinary, Oren, outlining, output, outreach, outweigh, ovarian, overexpression, oversee, overseeing, oversight, owed, owner, parachute, parallel, PARP, partner, passed, passive, path, penalty, pending, Pennsylvania, people, percentage, perception, permanent, perspective, PFIC, Pharma, phosphorylation, physical, physician, pill, placebo, play, Plc, pneumonia, poison, policy, political, population, Portability, pose, post, postpone, potent, power, PPACA, precedent, preceding, precision, preclude, predetermined, preempted, preissuance, premature, prematurely, premium, prescribe, prescribed, prescription, presence, President, presidential, pressure, prevalence, prevalent, prevent, prevented, preventing, prevention, priority, privacy, problem, procedural, procedure, procure, progressed, progression, prominently, promise, promising, promote, promoting, promotion, promotional, promptly, promulgation, proper, properly, prospective, proteomic, proximity, Pub, publicly, purge, purging, purpose, pursuit, put, pyrexia, qualification, quantity, question, radiation, radiotherapy, rapidly, rare, ratification, rationally, raw, reaction, recall, recession, recipient, reconsider, recordkeeping, recoup, recover, recovered, redeeming, redefine, redesigned, redesigning, reduction, redundant, refusal, refuse, regain, regional, regular, reimburse, reimbursed, reimbursement, reinterpreted, Relatedly, relaxation, release, relevant, reliance, reliant, relief, relieve, remedial, remediating, remove, removed, reoccur, repair, Repare, repeal, repeat, replace, replacement, reposition, reproduce, reputation, reputational, rescinding, resist, resistance, resolution, resource, respond, restarting, restitution, Restoration, restructured, restructuring, resume, resumption, retention, reveal, revocation, RMP, rolling, rotation, route, routine, Rubraca, rulemaking, safer, satisfactory, satisfy, SCET, Schade, Scott, scrutiny, secrecy, secret, sector, secure, securing, security, seize, seizure, Senior, serve, settlement, Shield, short, shorten, shortened, shortly, show, shown, sick, side, slower, SMX, specialty, spectrum, spending, sponsor, sponsored, staffing, statutory, stolen, stop, stopping, storage, store, stored, strand, strict, stricter, stringent, strong, structure, submission, suboptimal, subpart, substance, substantive, succeeded, sue, sued, suggest, suit, superior, superiority, supplement, supplementary, Supreme, surgery, surveillance, suspected, suspend, suspended, suspension, syndrome, synergistically, system, Taint, Talzenna, taxation, TCA, TCJA, temporarily, temporary, threat, threatened, threatening, tied, timeline, tort, toxic, toxicity, trademark, train, training, transmission, transmit, treasury, treaty, treble, trend, turn, turnover, type, UK, unacceptable, unannounced, unanticipated, unauthorized, unavailable, unclear, undergo, undesirable, unenforceability, unenforceable, unexpected, unfavorable, unidentified, unintended, Union, unmanaged, unnecessarily, unplanned, unpredictability, unpredictable, unproven, unpublished, unrecoverable, unrelated, unreliable, unresolved, unsafe, unsatisfactory, unsuccessful, untitled, unused, unvested, unwilling, upfront, upheld, user, USPTO, Utah, vendor, verification, version, viability, Vice, view, viewed, Virginia, visibility, vital, vomiting, vulnerability, vulnerable, warning, waste, website, whichever, wide, widely, widespread, withheld, workforce, worsen, writing, written, wrongfully, Zejula
Removed: bladder, France, gastric, involvement, lung, RSU, Stockholm